Latest Period
Q4 2025
Security Snapshot
Milestone Pharmaceuticals Inc. - Common Shares (MIST) Institutional Ownership
CUSIP: 59935V107
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
79
Shares (Excl. Options)
26,494,301
Price
$2.02
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Shares
- Symbol
- MIST on Nasdaq
- Shares outstanding
- 124,031,000
- Price per share
- $2.00
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 26,494,301
- Total reported value
- $53,565,472
- % of total 13F portfolios
- 0%
- Share change
- -7,634,652
- Value change
- -$15,312,984
- Number of holders
- 79
- Price from insider filings
- $2.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- MIST - Milestone Pharmaceuticals Inc. - Common Shares is tracked under CUSIP 59935V107.
- 79 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 79 to 20 between Q4 2025 and Q1 2026.
- Reported value moved from $53,565,472 to $3,107,871.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 79 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 59935V107?
CUSIP 59935V107 identifies MIST - Milestone Pharmaceuticals Inc. - Common Shares in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 59935V107:
Significant Owners of Milestone Pharmaceuticals Inc. - Common Shares (MIST) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 9.9% | -0.9% | $18,310,336 | +$7,029,150 | 9,155,168 | +62% | RTW Investments, LP | 30 Sep 2025 |
| Propel Bio Management, LLC | 9.9% | $21,001,011 | 8,861,186 | Propel Bio Management, LLC | 11 Jul 2025 | |||
| Adage Capital Management, L.P. | 10% | $17,318,128 | 8,659,064 | Adage Capital Management, L.P. | 30 Sep 2025 | |||
| Trails Edge Capital Partners, LP | 4.3% | -56% | $9,013,333 | -$6,226,884 | 5,333,333 | -41% | Trails Edge Capital Partners, LP | 20 Mar 2026 |
| INTEGRATED CORE STRATEGIES (US) LLC | 0.6% | $396,161 | 322,082 | Integrated Core Strategies (US) LLC | 31 Mar 2025 |
As of 31 Dec 2025, 79 institutional investors reported holding 26,494,301 shares of Milestone Pharmaceuticals Inc. - Common Shares (MIST). This represents 21% of the company’s total 124,031,000 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Milestone Pharmaceuticals Inc. - Common Shares (MIST) together control 20% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Propel Bio Management, LLC | 3.3% | 4,118,321 | -20% | 7.1% | $8,319,008 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.3% | 2,810,037 | -60% | 0.01% | $5,676,275 |
| RTW INVESTMENTS, LP | 2% | 2,506,102 | 0% | 0.05% | $5,062,326 |
| MARSHALL WACE, LLP | 1.3% | 1,656,821 | +290% | 0% | $3,346,777 |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 1,514,461 | +127% | 0% | $3,059,211 |
| Simplify Asset Management Inc. | 1.2% | 1,506,405 | -47% | 0.05% | $3,042,938 |
| JANE STREET GROUP, LLC | 0.88% | 1,093,230 | +168% | 0% | $2,208,324 |
| Pathstone Holdings, LLC | 0.82% | 1,017,040 | +1.7% | 0.01% | $2,104,421 |
| MORGAN STANLEY | 0.63% | 781,875 | -74% | 0% | $1,579,388 |
| Lion Point Capital, LP | 0.61% | 755,000 | +15% | 7.9% | $1,525,100 |
| TORONTO DOMINION BANK | 0.6% | 750,000 | 0% | 0% | $1,515,000 |
| Boxer Capital Management, LLC | 0.54% | 666,666 | 0% | 0.29% | $1,346,665 |
| Stonepine Capital Management, LLC | 0.53% | 662,666 | 1.1% | $1,338,585 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.52% | 643,300 | +151% | 0% | $1,299,466 |
| TWO SIGMA ADVISERS, LP | 0.5% | 619,592 | +165% | 0% | $1,251,576 |
| UBS Group AG | 0.4% | 491,868 | +24% | 0% | $993,574 |
| Point72 Asset Management, L.P. | 0.39% | 482,355 | 0% | $974,357 | |
| MILLENNIUM MANAGEMENT LLC | 0.32% | 402,635 | +0.27% | 0% | $813,323 |
| CITADEL ADVISORS LLC | 0.28% | 353,232 | -31% | 0% | $713,529 |
| GUARDIAN WEALTH ADVISORS, LLC / NC | 0.21% | 263,200 | +25% | 0.03% | $531,664 |
| Aptus Capital Advisors, LLC | 0.21% | 263,200 | +25% | 0% | $531,664 |
| Squarepoint Ops LLC | 0.2% | 249,344 | 0% | $503,675 | |
| GSA CAPITAL PARTNERS LLP | 0.19% | 236,138 | +200% | 0.04% | $477,000 |
| NOMURA HOLDINGS INC | 0.18% | 225,000 | 0% | $454,500 | |
| BNP PARIBAS FINANCIAL MARKETS | 0.18% | 221,951 | 0% | 0% | $448,341 |
Institutional Holders of Milestone Pharmaceuticals Inc. - Common Shares (MIST) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,611,266 | $3,107,871 | +$78,668 | $1.19 | 20 |
| 2025 Q4 | 26,494,301 | $53,565,472 | -$15,312,984 | $2.02 | 79 |
| 2025 Q3 | 34,138,461 | $68,276,752 | +$44,826,873 | $2.00 | 61 |
| 2025 Q2 | 11,817,806 | $22,925,663 | +$893,027 | $1.94 | 43 |
| 2025 Q1 | 11,824,370 | $9,461,152 | -$26,033,743 | $0.80 | 43 |
| 2024 Q4 | 24,552,580 | $57,943,143 | -$9,780,800 | $2.36 | 46 |
| 2024 Q3 | 28,677,385 | $43,589,418 | -$2,288,268 | $1.52 | 41 |
| 2024 Q2 | 30,178,631 | $39,890,373 | -$1,767,212 | $1.32 | 39 |
| 2024 Q1 | 31,068,273 | $55,610,121 | +$23,911,141 | $1.79 | 40 |
| 2023 Q4 | 17,804,637 | $29,733,304 | -$3,789,133 | $1.67 | 40 |
| 2023 Q3 | 19,572,198 | $60,672,803 | -$3,310,719 | $3.10 | 39 |
| 2023 Q2 | 20,687,365 | $58,958,957 | -$3,141,348 | $2.85 | 48 |
| 2023 Q1 | 21,710,779 | $85,540,237 | -$9,705,873 | $3.94 | 49 |
| 2022 Q4 | 23,737,827 | $94,006,246 | -$28,853,317 | $3.96 | 55 |
| 2022 Q3 | 20,398,285 | $187,452,026 | +$10,127,011 | $9.19 | 43 |
| 2022 Q2 | 20,825,690 | $127,165,640 | -$2,809,102 | $6.15 | 29 |
| 2022 Q1 | 21,048,124 | $135,124,913 | +$5,027,454 | $6.42 | 28 |
| 2021 Q4 | 20,243,658 | $132,596,706 | +$1,818,999 | $6.55 | 27 |
| 2021 Q3 | 19,956,009 | $113,947,594 | -$1,093,248 | $5.71 | 26 |
| 2021 Q2 | 20,148,798 | $110,818,750 | -$885,245 | $5.50 | 26 |
| 2021 Q1 | 20,284,874 | $117,447,374 | -$1,995,259 | $5.79 | 31 |
| 2020 Q4 | 20,571,334 | $137,829,226 | +$33,967,631 | $6.70 | 33 |
| 2020 Q3 | 15,483,607 | $113,344,014 | +$42,783,062 | $7.32 | 29 |
| 2020 Q2 | 9,754,497 | $36,871,064 | +$2,941,736 | $3.78 | 23 |
| 2020 Q1 | 9,242,998 | $17,005,883 | -$32,694,365 | $1.84 | 16 |
| 2019 Q4 | 14,399,976 | $230,543,150 | +$20,592,614 | $16.01 | 25 |
| 2019 Q3 | 13,069,709 | $239,626,222 | -$2,837,983 | $18.65 | 23 |
| 2019 Q2 | 13,080,914 | $350,497,172 | +$350,497,172 | $27.15 | 25 |